Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Imaging Canada Liquidating Corp IMRSQ

IMRIS Inc designs, manufactures and markets Image-guided therapy systems that improves the effectiveness of therapy delivery. Its main product is the Visius surgical theater. The company provides its products to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. The firm is focused on bringing enhanced visualization to the point of therapy delivery and is spread across Canada, United States, Europe and the Middle East and Asia-Pacific.


GREY:IMRSQ - Post by User

Comment by strelioffon Jul 05, 2011 1:36am
206 Views
Post# 18795185

RE: sleepy stock....

RE: sleepy stock....You made the Global Russell
https://www.russell.com/indexes/tools-resources/reconstitution/reconstitution-changes.asp


In support of the Company's priorities for the year, operating expensesare expected to increase over 2010 levels. Higher year over yearquarterly research and development expenditures are planned for theyear and are expected to be at levels similar to actual research anddevelopment expenditures incurred in Q1 2011. Spending in this areawill primarily be used to advance development of the MR guidedradiation therapy and MR guided surgical robotics products. Limitedincreases are anticipated in other operational areas and amortizationexpense will increase modestly.

<< Previous
Bullboard Posts
Next >>